Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients...
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by...
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for...
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to...
Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii...
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in...
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University...
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical...
Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows...
Philogen Provides Corporate Update Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial...
Philochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging Applications...
Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP...
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN...
Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun are on track with planned timelines in pivotal...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.